Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Trinovin is a dietary supplement developed by Novogen Laboratories for the maintenance of prostate health and urinary function in men, particularly those over 50 years of age. It contains a standardized extract derived from red clover (*Trifolium pratense*), providing 40mg per tablet of four specific isoflavones: biochanin A, formononetin, daidzein, and genistein. These phytoestrogens are intended to assist in relieving symptoms associated with benign prostatic hyperplasia (BPH), such as frequent urination, nocturia, and weak urinary stream. As a plant-based natural product, it is classified as a nutraceutical rather than a synthetic pharmaceutical compound and is marketed as a natural health product for age-related prostate support.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Trinovin.